文献速递白血病造血干细胞移植与细胞治疗

一种用于急性髓系白血病的模块化可控T细胞治疗平台

A modular and controllable T cell therapy platform for acute myeloid leukemia.
PubMed 文献 · Leukemia · 2021-01-07

该研究开发了一种针对急性髓系白血病的模块化可控MHC非限制性过继T细胞治疗平台,将合成激动受体转导的T细胞与靶向AML的串联单链可变片段构建体结合。该平台可选择性杀伤CD33+和CD123+ AML细胞系及患者来源的AML原始细胞,并在AML异种移植模型中显示持久应答和T细胞存续。

要点

  • SAR-T细胞联合AML靶向scFv构建体可选择性杀伤CD33+和CD123+ AML细胞。
  • 构建体交换可使SAR-T细胞重定向至替代靶点,得益于抗体片段短半衰期和可控性。
  • AML异种移植模型中观察到持久应答和SAR-T细胞存续。

核心结论

  • 模块化可控MHC非限制性过继T细胞治疗平台在AML中显示选择性杀伤和体内持久应答,值得进一步转化。

研究设计与样本

  • 临床前研究,开发合成激动受体转导T细胞联合AML靶向串联单链可变片段构建体的平台。
  • 体外评估对CD33+和CD123+ AML细胞系及患者来源AML原始细胞的杀伤。
  • 在AML异种移植模型中评估应答和T细胞存续。

主要发现

  • SAR-T细胞联合scFv构建体选择性杀伤CD33+和CD123+ AML细胞系及患者来源AML原始细胞。
  • AML异种移植模型中显示持久应答和SAR-T细胞存续。

临床怎么用

  • 该平台为AML提供模块化可控T细胞治疗策略,有待进一步转化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeted T cell therapy is highly effective in disease settings where tumor antigens are uniformly expressed on malignant cells and where off-tumor on-target-associated toxicity is manageable. Although acute myeloid leukemia (AML) has in principle been shown to be a T cell-sensitive disease by the graft-versus-leukemia activity of allogeneic stem cell transplantation, T cell therapy has so far failed in this setting. This is largely due to the lack of target structures both sufficiently selective and uniformly expressed on AML, causing unacceptable myeloid cell toxicity. To address this, we developed a modular and controllable MHC-unrestricted adoptive T cell therapy platform tailored to AML. This platform combines synthetic agonistic receptor (SAR) -transduced T cells with AML-targeting tandem single chain variable fragment (scFv) constructs. Construct exchange allows SAR T cells to be redirected toward alternative targets, a process enabled by the short half-life and controllability of these antibody fragments. Combining SAR-transduced T cells with the scFv constructs resulted in selective killing of CD33+ and CD123+ AML cell lines, as well as of patient-derived AML blasts. Durable responses and persistence of SAR-transduced T cells could also be demonstrated in AML xenograft models. Together these results warrant further translation of this novel platform for AML treatment.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Benmebarek MR, Cadilha BL, Herrmann M, et al. A modular and controllable T cell therapy platform for acute myeloid leukemia. Leukemia. 2021. PMID: 33414484. doi:10.1038/s41375-020-01109-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。